Latest Telehealth News

Epsilon Healthcare Limited reported a $3.25 million loss for 2024, reflecting the financial strain of voluntary administration and efforts to rebuild operations and client confidence.

EVE Health Group has reached a pivotal milestone with the first patient prescriptions of Dyspro™, its cannabinoid-based treatment for dysmenorrhoea and endometriosis, alongside launching an educational platform to support patients and clinicians.

HeraMED is fast-tracking its AI-driven maternity care technologies, including an early release of its AI Clinician Assistant and predictive models for high-risk pregnancies, aiming to revolutionize digital women’s health globally.

EVE Health Group has begun distributing Dyspro™, a novel cannabinoid-based treatment for dysmenorrhoea and endometriosis, through a national telehealth partnership. This launch targets a significant unmet need in women’s health with a growing global market.

LTR Pharma’s FY25 results reveal a transformative year highlighted by SPONTAN’s rapid absorption and strategic partnerships that pave the way for US market entry.

LTR Pharma Limited (ASX, LTP) reported significant progress in FY25, advancing its novel intranasal treatments for erectile dysfunction and expanding its commercial footprint in Australia and the US. The company secured key partnerships and capital raises, positioning itself for regulatory milestones and global market entry.

EMVision Medical Devices reported a sharp increase in FY25 losses alongside a 51% revenue drop, yet marked significant progress in clinical trials for its innovative brain scanners and secured $8 million in government grants to fuel commercialisation.

Doctor Care Anywhere has reported a profitable first half of 2025, driven by strong margin improvements and operational efficiencies. The telehealth provider’s strategic expansion and app enhancements signal promising growth ahead.

Doctor Care Anywhere Group PLC has reported its first-ever profit for the six months ended June 2025, marking a pivotal turnaround driven by operational efficiencies and pricing strategies despite a revenue dip.

Vitura Health Limited has announced its third fully franked dividend of 0.2 cents per share following a profitable FY2025, reinforcing its unique position in the medicinal cannabis sector. Shareholders are invited to participate in a discounted Dividend Reinvestment Plan.

Vitura Health reported modest revenue growth but a robust 23.5% increase in EBITDA for FY2025, fueled by key acquisitions and expanding telehealth services. Despite margin pressures in medicinal cannabis, the company’s strategic reset under new leadership sets the stage for further growth.

Vitura Health reported a modest revenue increase to $124 million for FY2025, while net profit dipped 5.35% due to margin pressures and investment in new platforms. The company declared a fully franked dividend and highlighted growth in telehealth and medical services.